Investigated
Can targeting Polθ inhibitors selectively kill ecDNA-driven tumors in patients?Source
Polθ inhibitors could exploit ecDNA-driven tumors' replication fragility to kill them selectively, proponents argue.
Oct 3, 2026
Source mix
6 of 8 institutional
Image: nature.com
The Story
The strongest evidence supports Polθ inhibition as a synthetic-lethal approach for homologous-recombination-deficient cancers, not yet as an ecDNA-specific treatment. Studies describe selective effects in HR-deficient models, molecular mechanisms for Polθ inhibition, and potential PARP-inhibitor combinations. Separate ecDNA research identifies replication and structural weaknesses, but the supplied sources do not connect those findings to patient responses to Polθ inhibitors.
- Polθ inhibition has shown selective toxicity toward HR-deficient cells and tumors in preclinical studies.
- The established biomarker rationale is HR deficiency, including BRCA-pathway defects, rather than ecDNA status itself.
- ecDNA-positive cancers have distinct replication and maintenance vulnerabilities, but the cited ecDNA study does not establish Polθ inhibitors as the relevant intervention in patients.
Deeper Insight
A more exploratory interpretation is that ecDNA-driven tumors may be unusually dependent on DNA-repair processes because circular, highly transcribed DNA creates replication stress and structural instability. This could make Polθ inhibition useful, potentially alongside PARP inhibition or other treatments. Yet the supplied evidence supports this as a testable hypothesis, not as demonstrated ecDNA selectivity or a proven patient treatment effect.
- Because ecDNA can generate replication-transcription conflicts and requires mechanisms that preserve its structure, repair-pathway dependence could be therapeutically exploitable.
- Polθ inhibitors create DNA-repair stress and selectively kill HR-deficient models, providing a mechanistic basis for investigating whether some ecDNA tumors are especially dependent on Polθ.
- ecDNA status might complement, rather than replace, HR-deficiency biomarkers when selecting patients for Polθ-inhibitor trials.
Sources · 8
- 6 Journals & institutions
- 2 Other / unclassified
What do these mean?
- Journals & institutions. Published in a peer-reviewed journal, or from a university, government body, court or other institution.
- Other / unclassified. A site we have not classified yet. This says nothing good or bad about it.
Featured · Primary source · nature.com
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors | Nature Communications
Journal · peer-reviewed
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors | Nature Communications ## Abstract The DNA damage response (DDR) protein DNA Polymerase θ (Polθ) is synthetic lethal with homologous recombination (HR) factors and is therefore a promising drug target
Read sourcePrimary source · pmc.ncbi.nlm.nih.gov
A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors - PMC
Journal · peer-reviewed
# A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors Nature Cancer. Published: 2021-06-17. 354 citations. ## Authors - Jia Zhou (Harvard University): h-index 17; 1,624 citations - Camille Gelot (Inserm): h-index 9; 853 citations - Constantia Pan
Read sourceAnalysis · mskcc.org
Scientists Uncover an Achilles’ Heel in Cancer’s ‘Rogue DNA’ | Memorial Sloan Kettering Cancer Center
Other
Scientists Uncover an Achilles’ Heel in Cancer’s ‘Rogue DNA’ | Memorial Sloan Kettering Cancer Center For appointments, call: 800-525-2225 (+1-800-525-2225) # Scientists Uncover an Achilles’ Heel in Cancer’s ‘Rogue DNA’ By Ian Demsky Wednesday, September 23, 2026 A team of MSK researchers from the l
Read source